Indoco Remedies Ltd. is a fully integrated, research-oriented pharma company. It manufactures and markets Active Pharmaceutical Ingredients (APIs) and Formulations (Finished Dosage Forms). It was incorporated in 1947, with its headquarters in Mumbai. During FY 2021-2022, the company generated a total revenue of Rs 1,543.08 crore, up 23.98% from the previous financial year, 2020-2021. On 31 October 2022, Indoco Remedies Ltd.’s market capitalisation was Rs 3,262 crore.
The company is listed on the Bombay Stock Exchange with the code 532612, and on the National Stock Exchange with the code INDOCO. It is also listed on the MCX Stock Exchange.
Indoco Remedies Ltd. has a well-built brand portfolio with a number of products in various therapeutic segments. It includes high-growth lifestyle segments like cardiovascular, musculoskeletal, anti-diabetics, central nervous system, dental care, and nutrition. The company has a strong presence in the international market across 55 countries and employs close to 6000 personnel with more than 300 skilled scientists. It has nine manufacturing facilities, of which three are for APIs and six for finished dosages.
On 30 June 2022, the company’s shareholding pattern showed a promoter holding of 58.69%, an FII holding of 1.17%, a DII holding of 18.08%, and a public holding of 22.06%. The leading promoter is Spa Holdings Pvt Ltd., with a 19.9% share. In the June 2022 quarter, mutual fund holdings decreased from 17.52% to 17.39%, while FPI holdings increased from 1.15% to 1.17%.
The company’s board of directors comprises Mr Suresh G Kare, Mr Sundeep V Bambolkar, Mr Rajiv P Kakodkar, Dr Anand Nadkarni, Mr D M Gavaskar, Mr Abhijit Yashwant Gore, Dr (Ms) Vasudha V Kamat, and Ms Aditi Kare Panandikar. The auditors are Gokhale & Sathe. As of 30 June 2022, the company’s total outstanding shares were 9.22 crores.
On 31 October 2022, the company’s share’s closing price was Rs 353.60 on BSE. On NSE, its closing price was Rs 354. The share touched a 52-week high of Rs 498 and a 52-week low of Rs 307.65. Investors earned a six-month return of -8.63% and a one-year return of -21.40%.
The company’s peers include Sun Pharmaceuticals Industries Ltd., Cipla Ltd., Dr Reddys Laboratories Ltd., and Divis Laboratories Ltd.
Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code: 07730), BSE Ltd (Member Code: 103) and Member of Multi Commodity Exchange of India Ltd.(Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Ms. Mamta Shetty, Contact number: 022-40701022, E-mail address: complianceofficer@icicisecurities.com. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Such representations are not indicative of future results. The securities quoted are exemplary and are not recommendatory. Investors should consult their financial advisers if in doubt about whether the product is suitable for them. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.
Invest
FAQ’s on Indoco Remedies Ltd Shares
